Peripheral T‐cell lymphoma gene expression profiling and potential therapeutic exploitations

Summary Peripheral T‐cell lymphomas constitute a heterogeneous group with regard to diagnosis, treatment and prognosis. Efforts have been made to combine novel techniques with cytology and immunochemistry in order to more precisely define these entities. Molecular profiling has contributed to novel insights in the biology of T‐cell lymphoma. Regarding anaplastic large cell lymphoma, low expression T‐cell receptor signalling and high STAT3 target signatures have been associated with the ALK‐positive subgroup. Gene expression profiling differentiates angioblastic T‐cell lymphoma from other T‐cell malignancies, suggests that the normal counterpart of lymphoma cells are follicular helper T cells, and supports the involvement of vascular endothelial growth factor deregulation in its physiopathology. In peripheral T‐cell lymphoma unspecified, gene profiling suggests the normal counterpart of tumour cells are activated CD4 + or CD8 + T‐lymphocytes, delineates prognostic groups depending on the proliferative signature, and suggests therapeutic options aimed at regulating nuclear factor‐κB and platelet‐derived growth factor receptor‐α phosphorylation. Gene expression profiling of primary cutaneous T cell lymphomas highlighted the importance of abnormal methylation patterns, suggested a pivotal role for JUNB/AP‐1, and defined a predictive model for response to interferon‐α. In conclusion, gene expression profiling is beginning to change the pathological classification, the prognosis profiles and the therapeutic approach in T‐cell lymphomas.